Infectious Complications in Head and Neck Cancer Patients Treated with Cetuximab: Propensity Score and Instrumental Variable Analysis

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Lee, Ching Chih ^a,b,c   Ho, Hsu Chueh ^a,c   Hsiao, Shih Hsuan ^a,c   Huang, Tza Ta ^d   Lin, Hon Yi ^a,c   Li, Szu Chin ^a,c   Chou, Pesus ^b   Su, Yu Chieh ^a,c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d Department of Oral and Maxillofacial Surgery   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRONCHITIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CELLULITIS; COHORT ANALYSIS; CONTROLLED STUDY; DIVERTICULITIS; DRUG FEVER; EPIGLOTTITIS; FEMALE; HEAD AND NECK CANCER; HERPES ZOSTER; HUMAN; INFECTION; INFECTION COMPLICATION; INFECTION RISK; INSTRUMENTAL VARIABLE ANALYSIS; LARYNGITIS; LARYNGOPHARYNGITIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OTITIS MEDIA; PANCREATITIS; PARASITOSIS; PHARYNGITIS; PNEUMONIA; PROPENSITY SCORE; RURAL AREA; SEPTICEMIA; SOCIOECONOMICS; TONSILLITIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; COMMUNICABLE DISEASES; COMORBIDITY; DATABASES, FACTUAL; FEMALE; HEAD AND NECK NEOPLASMS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; ODDS RATIO; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK; SOCIAL CLASS; TAIWAN;

EID: 84870361987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050163     Document Type: Article

References (27)

1. Bernier J, (2008) Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Nat Clin Prac Oncol 5: 705-713.
2. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
3. Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
4. Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, et al. (2011) Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Annals of Oncology 22: 712-717.
5. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, et al. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 11: 21-28.
6. Kang HJ, Park JS, Kim DW, Lee J, Jeong YJ, et al. (2012) Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients. Respir Med 106: 443-450.
7. Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BFt, et al. (2011) Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol 47: 961-966.
8. Burtness B, Goldwasser M, Flood W, Mattar B, Forastiere A, (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654.
9. Hoag J, Azizi A, Doherty T, Lu J, Willis R, et al. (2009) Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. Journal of Experimental & Clinical Cancer Research 28: 113.
10. Pfister D, Su Y, Kraus D, Wolden S, Lis E, et al. (2006) Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072-1078.
11. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, et al. (2001) Effectiveness of Chemotherapy for Advanced Lung Cancer in the Elderly: Instrumental Variable and Propensity Analysis. Journal of Clinical Oncology 19: 1064-1070.
12. Stukel TA, Fisher ES, Wenngerg DE, Alter DA, Gottlieb DJ, et al. (2007) Analysis of observational studies in the presence of treatment selection bias: Effects of invasive cardiac management on ami survival using propensity score and instrumental variable methods. JAMA: The Journal of the American Medical Association 297: 278-285.
13. NHI profile (2008). Available: http://www.nhi.gov.tw/english/webdata.asp?menu=11&menu_id=290&webdata_id=1884.Acessed 2008 July 31.
14. Deyo RA, Cherkin DC, Ciol MA, (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. Journal of Clinical Epidemiology 45: 613-619.
15. Chou FHC, Tsai KY, Su CY, Lee CC, (2011) The incidence and relative risk factors for developing cancer among patients with schizophrenia: A nine-year follow-up study. Schizophrenia Research 129: 97-103.
16. Liu CY, Huang YT, Chung YL, Chen YJ, Weng WS, et al. (2006) Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey (in Chinese). J Health Manage: 1-22.
17. Joffe MM, Rosenbaum PR, (1999) Invited Commentary: Propensity Scores. Am J Epidemiol 150: 327-333.
18. Rubin DB, (1993) Tasks in statistical inference for studying variation in medicine. Med Care 31: YS103-110.
19. Rubin DB, (1997) Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127: 757-763.
20. Angrist JD IC, Rubin DB, (1996) Identification of causal effects using instrumental variables. J Am Stat Assoc 91: 444-455.
21. DAgostino RB Jr, (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281.
22. Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, et al. (2009) Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 28: 113.
23. Bonner J, Harari P, Giralt J, Azarnia N, Shin D, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
24. Wang L, Chen YZ, Shi D, Shi XY, Zou Z, et al. (2011) Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis. Drugs R D 11: 317-326.
25. Argiris A, Karamouzis MV, Smith R, Kotsakis A, Gibson MK, et al. (2011) Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol 22: 2482-2488.
26. Raab G, Klagsbrun M, (1997) Heparin-binding EGF-like growth factor. Biochim Biophys Acta 1333: F179-199.
27. Lewkowicz P, Tchórzewski H, Dytnerska K, Banasik M, Lewkowicz N, (2005) Epidermal growth factor enhances TNF-α-induced priming of human neutrophils. Immunology Letters 96: 203-210.